Aims & Scope
Breast Disease is a peer-reviewed journal publishing papers on topics such as basic cellular and molecular biology, epidemiology, genetics, clinical research, imaging, and social and legal issues. The journal publishes research articles and reviews.
Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.
The ongoing work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries.
The editorial team believes that Breast Disease will be a timely and important addition to the information needs of scientists, clinicians, and policy makers.
Edison T. Liu, MD
President and CEO of The Jackson Laboratory
Bar Harbor, ME, USA
William G. Cance, MD
Professor and Chairman, Department of Surgery, University of Florida, Gainesville, FL
Charles V. Clevenger
Professor and Chair, Department of Pathology, Virginia Commonwealth University, Richmond, VA
Stan Lipkowitz, MD, PhD
Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
Diana M. Lopez, PhD
University of Miami School of Medicine, Department of Microbiology and Immunology, Miami, FL
Kathy D. Miller, MD
Assistant Professor of Medicine, Indiana Cancer Pavilion, Indianapolis, IN
Etta Pisano, MD
Associate Professor of Radiology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
Barbara Rimer, DrPH, MPH
Director, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
Andrew Seidman, MD
Memorial Sloan-Kettering Cancer Center, New York, NY
Wei-Zen Wei, PhD
Professor, Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI
Yosef Yarden, PhD
Professor, Department of Biological Regulation, Director, Dwek Institute for Cancer Therapy Research, Weizmann Institute of Science, Rehovot
Doug Yee, MD
Professor, Masonic Cancer Center, University of Minnesota, Minneapolis, MN
Cabell's Guide or Directory
Cancer Prevention and Control Database
Chemical Abstracts Service (CAS)
Epilepsy Education and Prevention Database
Health Education and Promotion Database
Prenatal Smoking Cessation Database
Ulrich's Periodicals Directory
Breast Disease is moving to an Open Access model in January 2024. From October 2023, submitting authors are required to pay an open access fee of US$500 / €500 (ex. VAT if applicable) for a CC-BY-NC license on acceptance for publication. Publishing under the CC BY 4.0 license is available at US$2150/ €2150 (ex. VAT if applicable) which is required by certain funders. Please check the author guidelines for more details.
Breast Disease Peer Review Policy
Breast Disease is a peer-reviewed journal. All articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known with the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.
All submitted manuscripts are automatically screened for plagiarism through iThenticate and, if found suitable for further consideration, to rigorous peer-review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be because the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel. Desk rejections are communicated within a few days after submission.
Reviewers are asked to judge a paper on at least:
- Originality, novelty and significance of results
- Technical quality of work
- Comprehensibility and presentation of the paper
- Overall impression
Based on the received reviews, a decision is made:
- Minor revisions required
- Major revisions required
- Revise and resubmit
They mean the following:
- Accept: The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
- Minor revisions required: The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors are successfully addressed. The revised manuscript will be examined by the Editors-in-Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- Major revisions required: The manuscript cannot be accepted for publication in its current form. However, a major revision which addresses all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission. The article may still be rejected in the revision round.
- Revise and resubmit: In its current form, the manuscript is not suitable for publication. A resubmission would require substantial revisions and is only encouraged in special cases. The resubmitted manuscript will be considered as a new submission.
- Reject: The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.
Authors are notified of the decision by the editorial office.
In-house submissions are subjected to the peer review process described above. Co-authors who are also members of the Editorial Board are not involved in any way with the peer review process of articles of their (co-)authorship.
Online-Only Journal – We are pleased to announce that Breast Disease has now transitioned to an online-only journal, with continuous publication with one issue per volume starting from 2022. This means that articles no longer go into pre-press and content is published in the issue as soon as it is finalized. You can now view the first article published in the new format in Volume 41.
Discover the latest articles published in the journal:
Genomic analysis of breast cancer patients from Kerala: A novel BRCA1 mutation detected
Vipin Gopinath, Adarsh Dharmarajan, Sangeetha Keloth Nayanar, Sobhith Velandi Kunnummal, Satheesan Balasubramanian, Deepak Roshan Valiyaparambil Gopi
5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006–2016)
Josephina G. Kuiper, Yannick J.P.G. van den Biggelaar, Maurice J.C. van der Sangen, Ernest J.T. Luiten, Sabine Siesling, Myrthe van Herk-Sukel, Adri C. Voogd, Ilse Mesters
A rapidly growing fibroadenoma in a pregnant woman: A case report
H.C. van Heusden, I.M. Brouwer de Koning, S.J.J. Mol, M.L. Rots, W.A. Draaisma, K. Bosscha
Desmoid fibroma simulating malignant breast neoplasm: A case report and literature review
Fábio Augusto Xerez Mota, Maria Stella Vasconcelos Sales Valente, Bárbara Bezerra Ricciardi, Bárbara Matos de Carvalho Borges, Enzo Studart de Lucena Feitosa, Pedro Lucena de Aquino, Paulla Vasconcelos Valente
A controversial ER negative PR positive molecular subtype of breast carcinoma—Report of two cases
Sanya Bhasin, Smita Chandra, Sunil Saini